Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: Which drug to recommend?

Expert Opinion on Drug Safety

Volumn 14, Issue 8, 2015, Pages 1259-1268

  Richette, Pascal ^a,b   Latourte, Augustin ^a,b   Frazier, Aline ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Acetaminophen; Cyclooxygenase inhibitors; NSAIDs; Osteoarthritis; Treatment

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN SYNTHASE INHIBITOR; ANALGESIC AGENT;

ANALGESIC ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; LIVER DISEASE; META ANALYSIS (TOPIC); NEPHROTOXICITY; OSTEOARTHRITIS; PATIENT RISK; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); RISK FACTOR;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; OSTEOARTHRITIS; RISK FACTORS;

EID: 84937207477     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1056776     Document Type: Review

References (99)

1. Hochberg MC. Osteoarthritis: the rheumatologist's perspective. Hss J 2011;8:35-6
2. Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2010;73:1323-30
3. Hoy DG, Smith E, Cross M, et al. The global burden of musculoskeletal conditions for 2010: An overview of methods. Ann Rheum Dis 2010;73:982-9
4. Hochberg MC. Mortality in osteoarthritis. Clin Exp Rheumatol 2008;26:S120-4
5. Nuesch E, Dieppe P, Reichenbach S, et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. Bmj 2011;342:d1165
6. Guillemin F, Rat AC, Roux CH, et al. The KHOALA cohort of knee and hip osteoarthritis in France. Joint Bone Spine 2012;79:597-603
7. Richette P, Hilliquin P, Bertin P, et al. Comparison of general practitioners and rheumatologists' prescription patterns for patients with knee osteoarthritis. BMC Musculoskelet Disord 2011;12:72
8. Johnson VL, Hunter DJ. The epidemiology of osteoarthritis. Best Pract Res Clin Rheumatol 2014;28:5-15
9. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79
10. Richette P. How safe is acetaminophen in rheumatology? Joint Bone Spine 2014;81:4-5
11. Richette P. Management of osteoarthritis: oral therapies. Rev Prat 2012;62:654-60
12. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44
13. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidencebased, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62
14. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007;15:981-1000
15. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15
16. Neame R, Zhang W, Doherty M. A historic issue of the Annals: three papers examine paracetamol in osteoarthritis. Ann Rheum Dis 2004;63:897-900
17. Bannwarth B. Acetaminophen or NSAIDs for the treatment of osteoarthritis. Best Pract Res Clin Rheumatol 2006;20:117-29
18. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64:465-74
19. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010;18:476-99
20. (UK) NCGC. Osteoarthritis: care and management in adults. National Institute for Health and Care Excellence (UK); London: 2014
21. Conaghan PG, Dickson J, Grant RL. Care and management of osteoarthritis in adults: summary of NICE guidance. Bmj 2008;336:502-3
22. Wise J. NICE keeps paracetamol in UK guidelines on osteoarthritis. Bmj 2014;348:g1545
23. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22:363-88
24. Towheed TE, Maxwell L, Judd MG et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006:CD004257
25. Bannuru RR, Schmid CH, Kent DM, et al. Comparative Effectiveness of Pharmacologic Interventions for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis. Ann Intern Med 2015;162:46-54
26. Richette P, Poitou C, Garnero P, et al. Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis 2011;70:139-44
27. Turtle EJ, Dear JW, Webb DJ. A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects. Br J Clin Pharmacol 2013;75:1396-405
28. Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002;162:2204-8
29. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46:500-7
30. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007;167:394-9
31. Dedier J, Stampfer MJ, Hankinson SE, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002;40:604-8. discussion 601-3
32. Sudano I, Flammer AJ, Periat D, et al. Acetaminophen increases blood pressurein patients with coronary artery disease. Circulation 2010;122:1789-96
33. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-87
34. Graham GG, Davies MJ, Day RO, et al. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology 2013;21:201-32
35. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. Faseb J 2008;22:383-90
36. Kim YJ, Lim KH, Kim MY, et al. Cross-reactivity to Acetaminophen and Celecoxib According to the Type of Nonsteroidal Anti-inflammatory Drug Hypersensitivity. Allergy Asthma Immunol Res 2014;6:156-62
37. Sanchez-Borges M. NSAID hypersensitivity (respiratory, cutaneous, and generalized anaphylactic symptoms). Med Clin North Am 2014; 94(4):853-64
38. Ferner RE, Dear JW, Bateman DN. Management of paracetamol poisoning. Bmj 2011;342:d2218
39. Prescott LF. Paracetamol: past, present, and future. Am J Ther 2000;7:143-7
40. Dart RC, Bailey E. Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy 2007;27:1219-30
41. Tiegs G, Karimi K, Brune K, Arck P. New problems arising from old drugs: second-generation effects of acetaminophen. Expert Rev Clin Pharmacol 2014;7:655-62
42. Craig DG, Bates CM, Davidson JS, et al. Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity. Br J Clin Pharmacol 2012;73:285-94
43. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: A randomized controlled trial. Jama 2006;296:87-93
44. Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf 2013;36:135-44
45. Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 2001;3:98-101
46. Rahme E, Barkun A, Nedjar H, et al. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec. Canada. Am J Gastroenterol 2008;103:872-82
47. Gonzalez-Perez A, Rodriguez LA. Upper gastrointestinal complications among users of paracetamol. Basic Clin Pharmacol Toxicol 2006;98:297-303
48. Doherty M, Hawkey C, Goulder M, et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. Ann Rheum Dis 2011;70:1534-41. This study shows that physicians should avoid the combination of acetaminophen and ibuprofen to alleviate pain in OA patients.
49. Hughes GJ, Patel PN, Saxena N. Effect of acetaminophen on international normalized ratio in patients receiving warfarin therapy. Pharmacotherapy 2011;31:591-7
50. Lopes RD, Horowitz JD, Garcia DA, et al. Warfarin and acetaminophen interaction: A summary of the evidence and biologic plausibility. Blood 2013;118:6269-73
51. Brattwall M, Turan I, Jakobsson J. Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004-2008-a retrospective patient record review. J Pain Res 2010;3:131-5
52. Wehling M. Non-steroidal antiinflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol 2014;70:1159-72. A nice review of NSAIDs toxicity.
53. Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U. S. Pharmacoepidemiol Drug Saf 2014;23:43-50
54. Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993;36:1196-206
55. Dieppe P, Cushnaghan J, Jasani MK, et al. A two-year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint. Br J Rheumatol 1993;32:595-600
56. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808
57. Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010;69:1459-64
58. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8. 2 p following 1528
59. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11
60. McGettigan P, Henry D. Use of nonsteroidal anti-inflammatory drugs that elevate cardiovascular risk: An examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013;10:e1001388
61. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis Meta-analysis of randomised trials. Bmj 2006;332:1302-8
62. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8:e1001098
63. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Bmj 2011;342:c7086
64. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 2013;16:821-47
65. Salvo F, Antoniazzi S, Duong M, et al. Cardiovascular events associated with the long-term use of NSAIDs: A review of randomized controlled trials and observational studies. Expert Opin Drug Saf 2014;13:573-85
66. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal antiinflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013;22:559-70
67. Reddy KS, Roy A. Cardiovascular risk of NSAIDs: time to translate knowledge into practice. PLoS Med 2013;10:e1001389
68. Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther 2013;15(Suppl 3):S2
69. Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev 2011;19:184-91
70. Chan CC, Reid CM, Aw TJ, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo An updated meta-analysis. J Hypertens 2009;27:2332-41
71. Grossman E, Messerli FH. Drug-induced hypertension: An unappreciated cause of secondary hypertension. Am J Med 2012;125:14-22
72. Lafrance JP, Miller DR. Selective and non-selective non-steroidal antiinflammatory drugs and the risk of acute kidney injury. Pharmacoepidemiol Drug Saf 2009;18:923-31
73. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013;15(Suppl 3):S3
74. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: A consensus statement using a meta-analytic approach. Ann Rheum Dis 2004;63:759-66
75. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal antiinflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9
76. Momeni M, Katz JD. Mitigating GI risks associated with the use of NSAIDs. Pain Med 2013;14(Suppl 1):S18-22
77. Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and nonselective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: A systematic review and meta-analysis. J Gastroenterol 2013;48:830-8
78. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007;8:73
79. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74
80. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006;119:255-66
81. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Jama 2000;284:1247-55
82. Rostom A, Muir K, Dube C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007;5:818-28. 828 e1-5; quiz 768
83. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAIDrelated ulcer complications. Am J Gastroenterol 2009;104:728-38
84. Blackler RW, Gemici B, Manko A, Wallace JL. NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. Curr Opin Pharmacol 2014;19:11-16
85. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal antiinflammatory drug-enteropathy. World J Gastroenterol 2013;19:1861-76
86. Park SC, Chun HJ, Kang CD, Sul D. Prevention and management of nonsteroidal anti-inflammatory drugsinduced small intestinal injury. World J Gastroenterol 2011;17:4647-53
87. Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial. Lancet 2010;376:173-9
88. Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133-41
89. Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007;25:1211-22
90. Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a doubleblind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008;135:1517-25
91. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-18
92. Medlock S, Eslami S, Askari M, et al. Co-prescription of gastroprotective agents and their efficacy in elderly patients taking nonsteroidal anti-inflammatory drugs: A systematic review ofobservational studies. Clin Gastroenterol Hepatol 2013;11:1259-69; e10
93. Wallace JL. Polypharmacy of osteoarthritis: the perfect intestinal storm. Dig Dis Sci 2013;58:3088-93
94. Roberts E, Delgado Nunes V, Buckner S, et al. Paracetamol: not as safe as we thought A systematic literature review of observational studies. Ann Rheum Dis 2015. doi: 10. 1136/annrheumdis-2014-206914 [Epub ahead of print]
95. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99
96. Duong M, Salvo F, Pariente A, et al. Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal antiinflammatory drugs in France. Br J Clin Pharmacol 2014;77:887-95
97. Laharie D, Droz-Perroteau C, Benichou J, et al. Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. Br J Clin Pharmacol 2010;69:295-302
98. Patrono C, Baigent C. Nonsteroidal antiinflammatory drugs and the heart. Circulation 2014;129:907-16
99. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52:1628-36